This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belkhiri, A. Articles by El-Rifai, W. Search for Related Content PubMed PubMed Citation Articles by Belkhiri, A. Articles by El-Rifai, W.

Darpp-32: a Novel Antiapoptotic Gene in Upper Gastrointestinal Carcinomas

¹ Digestive Health Center of Excellence and ² Department of Pathology, University of Virginia Health System, Charlottesville, Virginia and ³ Departments of Pathology and Medical Genetics, Haartman Institute, University of Helsinki and Helsinki University Central Hospital Laboratory Diagnostics, Helsinki, Finland

Requests for reprints: Wa'el El-Rifai, Digestive Health Center of Excellence, University of Virginia Health System, P.O. Box 800708, Charlottesville, VA 22908-0708. Phone: 434-243-6158; Fax: 243-6169; E-mail: wme8n{at}virginia.edu.

We show the molecular mechanisms involved in Darpp-32 overexpression and its biological role in upper gastrointestinal adenocarcinomas (UGC). A tumor tissue array of 377 samples was developed and used to detect DARPP-32 DNA amplification and protein overexpression, which occurred in 32% and 60% of UGCs, respectively. Concomitant overexpression of mRNA for Darpp-32 and its truncated isoform t-Darpp was observed in 68% of tumors (P < 0.001). When Darpp-32 and t-Darpp were overexpressed in AGS and RKO gastrointestinal cells, up to a 4-fold reduction in the apoptosis rate was observed (terminal deoxynucleotidyl transferase–mediated nick-end labeling and Annexin V assays) in response to camptothecin, sodium butyrate, and ceramide. However, the introduction of mutations in phosphorylation sites abrogated this effect. Expression of Darpp-32 and t-Darpp preserved the mitochondrial transmembrane potential and was associated with increased levels of Bcl2 protein. A reversal of Bcl2 protein level was obtained using small interfering RNAs for Darpp-32 and t-Darpp. Luciferase assays using the p53 and p21 reporter plasmids and probing of immunoblots with antibodies specific for p53 transcriptional targets, such as Hdm2 and p21, indicated that neither Darpp-32 nor t-Darpp interfere with p53 function. Altogether, we show more frequent mRNA and protein overexpression of Darpp-32 than DNA amplification, suggesting that, in addition to amplification, transcriptional or posttranscriptional mechanisms may play an important role. The expression of Darpp-32 and t-Darpp is associated with a potent antiapoptotic advantage for cancer cells through a p53-independent mechanism that involves preservation of mitochondrial potential and increased Bcl2 levels.

This article has been cited by other articles:

				A. Belkhiri, A. A. Dar, D. F. Peng, M. H. Razvi, C. Rinehart, C. L. Arteaga, and W. El-Rifai Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells Clin. Cancer Res., July 15, 2008; 14(14): 4564 - 4571. [Abstract] [Full Text] [PDF]

				A. Belkhiri, A. A. Dar, A. Zaika, M. Kelley, and W. El-Rifai t-Darpp Promotes Cancer Cell Survival by Up-regulation of Bcl2 through Akt-Dependent Mechanism Cancer Res., January 15, 2008; 68(2): 395 - 403. [Abstract] [Full Text] [PDF]

				A. Bogush, S. Pedrini, J. Pelta-Heller, T. Chan, Q. Yang, Z. Mao, E. Sluzas, T. Gieringer, and M. E. Ehrlich AKT and CDK5/p35 Mediate Brain-derived Neurotrophic Factor Induction of DARPP-32 in Medium Size Spiny Neurons in Vitro J. Biol. Chem., March 9, 2007; 282(10): 7352 - 7359. [Abstract] [Full Text] [PDF]

				N. Maqani, A. Belkhiri, C. Moskaluk, S. Knuutila, A. A. Dar, and W. El-Rifai Molecular Dissection of 17q12 Amplicon in Upper Gastrointestinal Adenocarcinomas Mol. Cancer Res., July 1, 2006; 4(7): 449 - 455. [Abstract] [Full Text] [PDF]